Minoryx announces dosing of the first patient with leriglitazone in the phase 2a study in Rett syndrome (TREE study) Barcelona, Spain – 4 March 2025 – Minoryx Therapeutics, a late-stage biotech company focused ... 04/03/2025
Leriglitazone has met the primary endpoint in NEXUS, the pivotal trial for pediatric patients with cerebral Adrenoleukodystrophy Statistically significant difference in arrested disease in leriglitazone treated patients ... 11/12/2024
Leriglitazone halts disease progression in adult patients with early cerebral adrenoleukodystrophy in compassionate-use study published in Brain In a French early-access program study, 10 of 13 patients were clinically ... 11/06/2024
15 Mar 2022 - 20 Mar 2022 AD/PD2022 International Conference on Alzheimer's and Parkinson's Diseases VIRTUAL
17 Oct 2021 - 19 Oct 2021 ANA 2021 - 16th Annual Meeting of the American Neurological Association VIRTUAL
Headquarters https://www.minoryx.com/content/imgs/mail/logo.png Av. Ernest Lluch 32 08302 Mataró (Barcelona) Spain
Belgian R&D Site https://www.minoryx.com/content/imgs/mail/logo.png Ave. Jean Mermoz 32 6041 Gosselies (Charleroi) Belgium